聚焦超声用于神经肿瘤学中血脑屏障破坏的方法学与伦理挑战
本文通过综合文献综述,采用IDEAL-D框架、SYRCLE和ROBINS-I工具评估聚焦超声(FUS)在神经肿瘤学中开放血脑屏障的研究。共纳入19项已发表研究和12项注册试验,发现FUS可成功破坏血脑屏障、增加药物递送并改善生存率,但动物研究存在高偏倚风险,多数人体研究因缺乏盲法和样本异质性存在高偏倚风险,且伦理和方法学报告不足,无研究达到IDEAL-D阶段终点。
要点
- FUS可成功破坏血脑屏障、增加药物递送并改善生存率。
- SYRCLE分析显示动物研究存在高偏倚风险。
- ROBINS-I分析发现多数人体研究因缺乏盲法和样本异质性存在高偏倚风险。
核心结论
- FUS在增强脑内药物递送方面有前景,但其开发与实施必须使用既定伦理和方法学框架遵循严格安全标准。
- IDEAL-D、SYRCLE和ROBINS-I工具的互补使用表明动物和人体研究均存在高偏倚风险和伦理局限性,突出需要进一步改进研究设计以在神经肿瘤学中安全实施FUS。
研究设计与样本
- 综合文献综述,纳入19项已发表研究和12项注册试验,并使用IDEAL-D框架、SYRCLE和ROBINS-I工具进行评估。
主要发现
- FUS demonstrated successful BBB disruption, increased drug delivery, and improved survival rates.
- SYRCLE分析显示动物研究存在高偏倚风险。
- ROBINS-I分析发现多数人体研究因缺乏盲法和样本异质性存在高偏倚风险。
- 15项临床前0期研究中仅6项获得正式伦理批准,仅5项遵循动物护理政策。
- 1期研究和1/2a期研究均未提供患者数据保密信息。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Focused ultrasound (FUS) shows promise for enhancing drug delivery to the brain by temporarily opening the blood-brain barrier (BBB), and it is increasingly used in the clinical setting to treat brain tumours. It remains however unclear whether FUS is being introduced in an ethically and methodologically sound manner. The IDEAL-D framework for the introduction of surgical innovations and the SYRCLE and ROBINS-I tools for assessing the risk of bias in animal studies and non-randomized trials, respectively, provide a comprehensive evaluation for this. OBJECTIVES AND METHODS: A comprehensive literature review on FUS in neuro-oncology was conducted. Subsequently, the included studies were evaluated using the IDEAL-D framework, SYRCLE, and ROBINS-I tools. RESULTS: In total, 19 published studies and 12 registered trials were identified. FUS demonstrated successful BBB disruption, increased drug delivery, and improved survival rates. However, the SYRCLE analysis revealed a high risk of bias in animal studies, while the ROBINS-I analysis found that most human studies had a high risk of bias due to a lack of blinding and heterogeneous samples. Of the 15 pre-clinical stage 0 studies, only six had formal ethical approval, and only five followed animal care policies. Both stage 1 studies and stage 1/2a studies failed to provide information on patient data confidentiality. Overall, no animal or human study reached the IDEAL-D stage endpoint. CONCLUSION: FUS holds promise for enhancing drug delivery to the brain, but its development and implementation must adhere to rigorous safety standards using the established ethical and methodological frameworks. The complementary use of IDEAL-D, SYRCLE, and ROBINS-I tools indicates a high risk of bias and ethical limitations in both animal and human studies, highlighting the need for further improvements in study design for a safe implementation of FUS in neuro-oncology.
引用
- Thavarajasingam SG, Kilgallon JL, Ramsay DSC, et al. Methodological and ethical challenges in the use of focused ultrasound for blood-brain barrier disruption in neuro-oncology. Acta Neurochir (Wien). 2023. PMID: 37672093. doi:10.1007/s00701-023-05782-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。